INOVIO $20M public offering
Analysis based on 6 articles · First reported Jul 29, 2026 · Last updated Jul 30, 2026
The offering dilutes existing shareholders, potentially lowering the stock price in the short term. However, the capital raised may fund INOVIO's DNA medicine pipeline, supporting long-term growth.
Rhythm Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 21,052,632 shares of common stock and accompanying warrants to purchase up to 42,105,264 shares of common stock at a combined price of $0.95 per share and warrant. The gross proceeds are expected to be approximately $20.0 million. Piper Sandler Companies is acting as sole manager. The offering is expected to close on July 31, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard